DRTS Stock Forecast & Price Target

Alpha Tau Medical is viewed positively because its Alpha DaRT platform is generating meaningful clinical proof-of-concept across multiple difficult solid tumors, including 100% ORR and 18.2 months of median overall survival in HNSCC when combined with pembrolizumab, while also showing no serious Alpha DaRT-associated adverse events. The company also has several near-term catalysts in 2H26 and late 2026 or early 2027, including REGAIN, IMPACT, and ReSTART updates, plus a first U.S. prostate cancer patient treated, which could broaden regulatory and commercial optionality. Despite a 2Q26 net loss of $45.8M, the stock’s fundamentals are supported by advancing pivotal and pilot studies, clearance to expand REGAIN enrollment, and a potential PMA pathway under Breakthrough Device designation.

Alpha Tau Medical is a clinical-stage oncology company whose valuation depends heavily on Alpha DaRT, yet that asset is still subject to major clinical, regulatory, and commercialization uncertainty across key indications such as SCC and GBM. The cited DCF framework relies on aggressive assumptions, including a 15% discount rate, 2% terminal growth, and approval probabilities of 75% for SCC, 60% for GBM, and 100% for head & neck cancer in Japan, which leaves meaningful downside if development slips or adoption is weaker than expected. With only $104.8M cash in one scenario and $80.2M in another, 92.4M or 90.2M shares outstanding, and explicit dilution risk, the downside outlook reflects a business with limited financial cushion and high execution risk.